TCGA-QK-A64Z-01A-11R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.146347032
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- INTERFERON_GAMMA_RESPONSE+0.310
- PROTEIN_SECRETION+0.270
- DNA_REPAIR+0.230
- OXIDATIVE_PHOSPHORYLATION+0.210
- NOTCH_SIGNALING+0.180
- UNFOLDED_PROTEIN_RESPONSE+0.180
- APICAL_SURFACE+0.130
- MYC_TARGETS_V2+0.130
- P53_PATHWAY+0.090
Top 10 suppressed
- MYOGENESIS-0.370
- IL2_STAT5_SIGNALING-0.350
- E2F_TARGETS-0.340
- MITOTIC_SPINDLE-0.300
- KRAS_SIGNALING_UP-0.280
- G2M_CHECKPOINT-0.270
- ALLOGRAFT_REJECTION-0.250
- HYPOXIA-0.250
- XENOBIOTIC_METABOLISM-0.240
- ESTROGEN_RESPONSE_EARLY-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202456 | — | — | 0.724 |
| 2 | SRR1516087 | — | — | 0.702 |
| 3 | SRR23303762 | — | — | 0.698 |
| 4 | TCGA-T2-A6X2-01A-12R-A34R-07 | — | — | 0.670 |
| 5 | X7c156f05.aaca.4c79.bdb2.94044d5422e8 | — | cohortA1 | 0.667 |
| 6 | TCGA-ZF-A9R5-01A-12R-A42T-07 | — | — | 0.662 |
| 7 | SRR6013584 | — | cohortA1 | 0.654 |
| 8 | R10 | — | — | 0.643 |
| 9 | 0a4a9b5b-90d9-4789-af04-f931433808c1 | — | — | 0.634 |
| 10 | SRR8942997 | — | — | 0.634 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.050 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |